

PRESS RELEASE

24 June 2021 11:05:00 CEST

SENZIME PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM

Uppsala, 24 June 2021. On 23 June 2021, Senzime AB (publ) announced that Nasdaq Stockholm's Listing Committee had approved that the company's shares are admitted to trading on Nasdaq Stockholm's main market, conditioned upon customary conditions being fulfilled. The prospectus prepared in connection with the listing has today been approved and registered by the Swedish Financial Supervisory Authority and is now available on Senzimes website www.senzime.com and will be made available on the Swedish Financial Supervisory Authority's website www.fi.se.

Link to prospectus (only available in Swedish): [[Prospectus Senzime AB 2021](#)]

The first day of trading on Nasdaq Stockholm's main market is scheduled for Wednesday 30 June 2021 and the last day of trading on Nasdaq First North Growth Market is scheduled for Tuesday 29 June 2021. The shares will be traded under the same ticker (SEZI) and ISIN-code (SE0002478776). There is no offering or issue new shares in connection with the list change, and shareholders in Senzime do not need to take any actions.

Advokatfirman Lindahl has acted as legal advisor in connection with the listing on Nasdaq Stockholm.

N.B. English translation is for convenience purposes only.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Phone: +46 (0) 70-813 34 17, e-post: pia.renaudin@senzime.com

Erik Bergman, CFO

Phone: +46 (0) 73-258 81 59, e-mail: erik.bergman@senzime.com

About Sensime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Sensime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Sensime. www.senzime.com

Attachments

SENZIME PUBLISHES PROSPECTUS IN CONNECTION WITH THE LISTING ON NASDAQ STOCKHOLM